Savior Lifetec Corp. · TPEX:4167
Savior Lifetec — Q3 2022 Earnings Presentation
24 slides from Savior Lifetec's earnings presentation, Nov 10, 2022
Slide 1: Investor Conference
Investor Conference November 10, 2022
Slide 2: Disclaimer
Disclaimer This presentation has been provided by Savior Lifetec Corporation (SLC) for informational purposes only. It is not an offer to buy or sell or a solicitation of an offer to buy or sell any security issued by SLC or other parties. This presentation may contain forward-looking statements whi
Slide 3: Agenda
Agenda About SLC Group • Industry Position Financial Overview • 2022 Q3 Financial Highlight Market Outlook & Product Strategy • Carbapenem Product Strategy • Specialty Pharma 3
Slide 4: About SLC Group
About SLC Group • Industry Position Financial Overview • 2022 Q3 Financial Highlight Market Outlook&Product Strategy • Carbapenem Product Strategy • Specialty Pharma 4
Slide 5: SLC – Establish SLC BioPharm
SLC – Establish SLC BioPharm Established Since January 30, 2004 SLC IPO Time (TPEx) September 8, 2015 (4167) Business Focus Carbapenem Drug Products Carbapenem New Drug Products CDMO 美國培南市場的契機 SLC Established Since February 8, 2022 BioPharm Business Focus Specialty Drug Products CRO 5
Slide 6: SLC-- Management Team
SLC-- Management Team Regulatory Compliance/Drug Development SLC BioPharm YongFa Chen 25+ Yrs and Process/Pharmaceutical Development Chairman and G.M. Strategy Planning Production / Regulatory Compliance / SLC Freon Chen 25+ Yrs Pharmaceutical Development Strategic General Manager Planning SLC Regul
Slide 7: SLC – Process Improvement
SLC – Process Improvement capacity Process improvement： • Reduced solvent usage and no toxic output • Shorten process time, increase batch feed, and reduce carbon emissions +100% original capacity new capacity 7
Slide 8: Leading Specialty Pharma Company in Taiwan
Leading Specialty Pharma Company in Taiwan 1 Taiwan’s Largest Injectable Drug Manufacturer and Exporter to the US Market Taiwan's First and the Only One Vertically-Integrated Specialty Pharma Company: 2 Sterile API + Finished Dosage Form (Injectable) + Self-Owned ANDA 3 Top 3 Carbapenem Injectable D
Slide 9: Financial Overview
About SLC Group • Industry Position Financial Overview • 2022 Q3 Financial Highlight Market Outlook&Product Strategy • Carbapenem Product Strategy • Specialty Pharma 9
Slide 10: Consolidated Income Statement
Consolidated Income Statement ($mn) 3Q22 2Q22 3Q21 Net Sales 348 356 379 COGS 304 304 364 Gross Profit 44 52 15 Gross Margin 12% 15% 4% Operating Expense 56 55 79 Operating Income (12) (3) (64) Operating Margin (4%) (1%) (17%) Non-Op Income (Expense) 145 1 7 Net Income 133 (2) (57) Net Margin 38% -
Slide 11: Consolidated Income Statement
Consolidated Income Statement ($mn) 2022前三季 2021前三季 Net Sales 1,012 1,409 COGS 911 1,128 Gross Profit 101 281 Gross Margin 10% 20% Operating Expense 174 225 Operating Income (73) 56 Operating Margin (7%) 4% Non-Op Income (Expense) 151 (17) Net Income 77 39 Net Margin 8% 3% EPS 0.24 0.12 11
Slide 12: Consolidated Balance Sheet Summary
Consolidated Balance Sheet Summary ($mn) 2022/9/30 2021/12/31 2021/9/30 Cash and cash equivalents 1,089 491 563 Net accounts receivable 304 486 451 Inventory 1,084 1,307 1,386 合併綜合損益摘要 Property, plant and equipment 1,052 1,174 1,721 Corporate bonds payable 527 524 522 Total Assets 4,413 4,538 4,669
Slide 13: Important Financial Indicators
Important Financial Indicators 2022/9/30 2021/12/31 2021/9/30 AR Turnover (Day) 108 112 101 Return on Assets (%) 2.67% 0.5% 1.41% 合併綜合損益摘要 Return on Equity (%) 3.07% 0.3% 1.57% Debt Ratio (%) 23.18% 27.01% 28.50% 13
Slide 14: Market Outlook & Product Strategy
Company Overview • Industry Position Financial Overview • 2022 Q3 Financial Highlight Market Outlook&Product Strategy • Carbapenem Product Strategy • Specialty Pharma 14
Slide 15: Carbapenem Are Antibiotics Of Last Resort
Carbapenem Are Antibiotics Of Last Resort Gram Positive Cocci Gram Negative Bacilli E. Coli, Klebsiella Anaerobes MRSA MSSA Streptococci Proteus Pseudomonas ESCAPPM Amoxicillin (Penicillin) Amoxicillin-Clavulanate Amoxicillin-Clavulanate (Penicillin + BLI) (Penicillin + BLI) Piperacillin-Tazobactam
Slide 16: Vertically Integrated Specialty Pharma Model
Vertically Integrated Specialty Pharma Model 1 2 3 4 Chemical Synthesis Aseptic API Process Aseptic Filling Line Market (SLC Label) + Crude API API(Sterile Bulk) Injectable (Sterile) Customer’s Filling Line Market Market (Customer’s Label) (Customer’s Label) 16
Slide 17: Core Technology: Aseptic Lyophilization
Core Technology: Aseptic Lyophilization From API Synthesis to Injectable Filling GMP “ Grade A “Aseptic Process API Manufacturing Aseptic API Process Aseptic Filling ▪ Chemical Synthesis ▪ Aseptic Lyophilization ▪ Injectable ▪ Sterile Dry Powder Raw Ertapenem Material API Ertapenem Filtration (Steri
Slide 18: Meropenem Global Market Growth
Meropenem Global Market Growth 2022 (Q1 MAT) Global Market US$ 1,880 mn +8.4% (Metric Tons) CAGR 250 200 142 152 150 118 120 其他 100 歐洲市場銷量 50 68 70 美國市場銷量 54 57 22 22 23 25 0 2019 2020 2021 2022 Source: New Port, 2022 Q1 MAT 18
Slide 19: Ertapenem Global Market
Ertapenem Global Market 2022 (Q1 MAT) Global Market US$ 335 mn (Metric Tons) 25 +1.2% GR 20 15 11.9 11.2 6.2 6.2 其他 10 歐洲市場銷量 2.4 2.3 2.4 2.4 5 美國市場銷量 5.8 5.9 5.7 5.9 0 2019 2020 2021 2022 Source: New Port, 2022 Q1 MAT 19
Slide 20: 2022 Ertapenem Territories
2022 Ertapenem Territories
Slide 21: 2023-24 Ertapenem Territories
2023-24 Ertapenem Territories
Slide 22: New Oral Antibiotics Market Potential
New Oral Antibiotics Market Potential New Oral Penem Antibiotics Will Replace Oral Quinolone Antibiotics US Patient Number US Market Size Market Segment (Est. by UTI Prevalence Rate) (US$) 「Go Home」 1,000,000 ~2,400,000,000 「Stay Home」 1,200,000 ~2,880,000,000 New Oral Penem Antibiotic Other CDMO Op
Slide 23: SLC BioPharm New Product: Focus on US Specialty Pharma Market
SLC BioPharm New Product: Focus on US Specialty Pharma Market Has Selected 6Specialty Drugs to Develop Will File DMFs in 2023 ANDA/NDA US Market Size Product No. API Dosage Form Indication DMF Filing Filing (2021/06~2022/06) SLC-021 Small Extended release Extended release depot for 2023 Q4 TBD US$29
Slide 24: Thank you
Thank you